Audioboom
OncLive® On AirEpisodes
Episodes of OncLive® On Air
Mark All
Search Episodes...
Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.
Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.
Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.
Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.
Dr Rosenberg discusses current standard strategies for treating patients with nasopharyngeal cancer, the evolving role of toripalimab in this treatment paradigm, and how future advances in nasopharyngeal cancer management may impact the head an
OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.
Dr Paik discusses key findings from the phase 2 VISION trial investigating frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping alterations, real-world data from the TOGETHER pooled analysis of tepotinib vs other frontline
Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.
Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed.
Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, t
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.
Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and more.
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that ge
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting t
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us